Alkermes plc (NASDAQ:ALKS) Stock Has Consensus Target Price of $55.06

Shares of Alkermes plc (NASDAQ:ALKS – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $55.73.

Several research firms have weighed in on ALKS. Stifel Nicolaus restated a “buy” rating and set a $63.00 target price (up from $45.00) on shares of Alkermes in a report on Monday, July 20th. Wells Fargo & Company upped their price target on Alkermes from $65.00 to $68.00 and gave the company an “overweight” rating in a research note on Wednesday, November 4th. JPMorgan Chase & Co. increased their price target on shares of Alkermes from $60.00 to $61.00 and gave the company a “neutral” rating in a research report on Wednesday, July 29th. Weiss Ratings reissued a “hold (c)” rating on shares of Alkermes in a research note on Wednesday, November 4th. Finally, Truist Financial started coverage on shares of Alkermes in a research note on Friday, October 16th. They set a “buy” rating and a $55.00 price objective on the stock.

Check Out Our Latest Analysis on Alkermes

Insider Activity

In other Alkermes news, EVP David Gaffin sold 2,035 shares of the stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $46.17, for a total transaction of $93,955.95. Following the transaction, the executive vice president owned 219,353 shares in the company, valued at $10,127,528.01. This trade represents a 0.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Craig Hopkinson sold 9,000 shares of Alkermes stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $46.99, for a total value of $422,910.00. Following the sale, the executive vice president directly owned 65,389 shares of the company’s stock, valued at $3,072,629.11. This represents a 12.10% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 15,103 shares of company stock worth $697,973 over the last 90 days. 4.59% of the stock is owned by company insiders.

Institutional Investors Weigh In On Alkermes

Hedge funds and other institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP increased its position in shares of Alkermes by 2.5% in the first quarter. Dimensional Fund Advisors LP now owns 4,522,378 shares of the company’s stock worth $159,850,000 after purchasing an additional 109,595 shares during the period. Commodore Capital LP increased its holdings in Alkermes by 18.3% in the 1st quarter. Commodore Capital LP now owns 4,200,000 shares of the company’s stock valued at $148,512,000 after buying an additional 650,000 shares during the period. First Trust Advisors LP increased its holdings in Alkermes by 104.2% in the 1st quarter. First Trust Advisors LP now owns 2,968,785 shares of the company’s stock valued at $104,976,000 after buying an additional 1,514,783 shares during the period. Affinity Asset Advisors LLC raised its position in shares of Alkermes by 35.0% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,350,000 shares of the company’s stock valued at $47,736,000 after buying an additional 350,000 shares in the last quarter. Finally, Public Sector Pension Investment Board raised its position in shares of Alkermes by 59.8% in the 3rd quarter. Public Sector Pension Investment Board now owns 1,082,205 shares of the company’s stock valued at $43,158,000 after buying an additional 404,800 shares in the last quarter. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Alkermes Price Performance

Shares of NASDAQ ALKS opened at $47.03 on Wednesday. Alkermes has a 1 year low of $27.00 and a 1 year high of $55.67. The firm’s 50-day moving average is $43.67 and its 200-day moving average is $41.13. The company has a current ratio of 2.42, a quick ratio of 2.02 and a debt-to-equity ratio of 0.79. The firm has a market capitalization of $7.90 billion, a PE ratio of -2,350.32 and a beta of 0.32.

Alkermes (NASDAQ:ALKS – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.17. Alkermes had a negative net margin of 0.02% and a positive return on equity of 0.40%. The firm had revenue of $480.13 million for the quarter, compared to analysts’ expectations of $463.48 million. During the same period last year, the firm earned $0.49 earnings per share. The business’s revenue for the quarter was up 21.8% on a year-over-year basis. Equities analysts expect that Alkermes will post -0.52 EPS for the current year.

About Alkermes

(Get Free Report)

Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for neuroscience-related conditions, including serious mental illness and addiction. Founded in 1987, the company has operations in the United States and Ireland, with its corporate headquarters in Dublin and major U.S. operations in Massachusetts. Its marketed medicines include Vivitrol, an extended-release injectable formulation of naltrexone used to treat alcohol dependence and to prevent relapse to opioid dependence after detoxification; Aristada, an injectable treatment for schizophrenia in adults; and Lybalvi, a medicine for schizophrenia and bipolar I disorder in adults.

Recommended Stories

Analyst Recommendations for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.